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Background: Omalizumab is effective and well-tolerated in children with moderate to severe allergic
asthma. However, the effects of long-term treatment with omalizumab in this population haven't been
well investigated. The objective of this study is to evaluate the long-term safety, efﬁcacy, pharmacoki-
netics and pharmacodynamics of omalizumab in children with uncontrolled severe asthma.
Methods: Thirty-eight Japanese children (aged 7e16 years) who completed the 24-week treatment core
study were included in an uncontrolled extension study, in which treatment with omalizumab continued
until the pediatric indication was approved in Japan (ClinicalTrials.gov number: NCT01328886).
Results: Thirty-ﬁve patients (92.1%) completed the extension study. The median exposure throughout
the core and extension studies was 116.6 weeks (range, 46.9e151.1 weeks). The most common adverse
events were nasopharyngitis, inﬂuenza, upper respiratory tract infection, and asthma. Serious adverse
events developed in 10 patients (26.3%), but resolved completely with additional treatments. Incidence
of adverse events didn't increase with extended exposure with omalizumab. Twenty-nine patients
(76.3%) achieved completely- or well-controlled asthma compared with 9 patients (23.7%) at the start of
the extension study. QOL scores, the rates (per year) of hospitalizations and ER visits were signiﬁcantly
improved compared with the baseline of the core study [39.0 vs 48.0 (median), p < 0.001 for QOL, 1.33 vs
0.16, p < 0.001 for hospitalization, 0.68 vs 0.15, p ¼ 0.002 for ER visits]. Remarkably, the mean total IgE
level showed a decreasing trend while exposure to omalizumab remained at steady-state.Fukuoka National Hospital, 4-39-1 Yakatabaru, Minami-Ku, Fukuoka 811-1394, Japan.
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FEV1, forced expiratory volume in 1 s;
ICS, inhaled corticosteroid; JPAC, Japanese
pediatric asthma control program;
JPGL, Japanese pediatric guideline for the
treatment and management of asthma;
LOCF, last observation carried forward;
LTRA, leukotriene receptor antagonist;
LABA, long-acting b2-agonist; QOL, quality
of life; SAEs, serious adverse eventsFig. 1. Study design. This study was extension to the co
omalizumab at 16 weeks after the last dosing. The exte
weeks after the last dosing. Start of the extension study
the core study, and the treatment with omalizumab lasConclusions: Long-term treatment with omalizumab is well-tolerated and effective in children with
uncontrolled severe allergic asthma. No new safety ﬁndings were identiﬁed.
Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma in children is often poorly controlled, usually as a result
of under-treatment with controller medications and poor inhaler
technique; however, some children have poor asthma control
despite current optimal therapies with high-dose inhaled cortico-
steroid (ICS) plus long-acting b2-agonist (LABA) or leukotriene re-
ceptor antagonist (LTRA) or theophylline.1,2 Uncontrolled severe
asthma results in a high risk of asthma exacerbations and impaired
quality of life.3 Asthma exacerbations are associated with hospital
admissions and emergency room (ER) visits,4 time lost from work
and school5 and decline in lung function.6 In addition, a history of
asthma exacerbation increases the risk of further asthma exacer-
bations requiring hospitalizations, ER visits or corticosteroids
bursts.7 Asthma exacerbations are frequently treated with systemic
[oral or intravenous] corticosteroids, which, if used in multiple
bursts over a period of years, could be associated with a reduction
in bone mineral accretion and increased risk for osteopenia.8
Chronic use of high dose ICS was also found to result in a sup-
pression of growth velocity and adrenal function.8,9
Omalizumab, a humanized monoclonal anti-IgE antibody, is
indicated for the treatment of moderate to severe allergic asthma
that is inadequately controlled despite current recommended
therapies.10e12 Several randomized placebo-controlled studies,
which have shown a signiﬁcant decrease in asthma exacerbations,
have established omalizumab as an effective and well-tolerated
agent for use as add-on therapy in pediatric patients with moder-
ate to severe asthma.13e15 We also have previously demonstrated
the noticeable clinical effects of omalizumab in Japanese children
(6e15 years) with severe asthma in a 24-week treatment, single-re study which included a 2-week
nsion study consisted of a treatmen
(restarting of treatment with omaliz
ted until omalizumab was approvedarm, open-label phase III study.16 However, especially in child-
hood asthma population, effects of long-term treatment
with omalizumab have remained to be investigated. Therefore,
to evaluate comprehensively the long-term safety, efﬁcacy, phar-
macokinetics and pharmacodynamics of omalizumab in children
with severe uncontrolled asthma in a condition close to a real-life,
we conducted a single-arm, open-label phase III extension study
following the 24-week core study.16
Methods
Study design and patients
This multicenter, single-arm, open-label phase III study, con-
ducted at 15 centers in Japan, was an extension to the 24-week
treatment core study in Japanese children (6e15 years) with un-
controlled severe allergic asthma despite ICS (>200 mg/day ﬂuti-
casone propionate [FP] or equivalent) and two or more controller
therapies out of LTRA, LABA, theophylline, sodium cromoglycate,
and oral corticosteroid.16 The extension study consisted of a treat-
ment period and an optional follow-up investigation for anti-
omalizumab antibodies at 16 weeks after the last dosing (Fig. 1).
The start of the extension study (restarting of treatment with
omalizumab) was on the same day of the follow-up investigation
for anti-omalizumab antibodies of the core study, and adminis-
tration of omalizumab continued until the pediatric indication was
approved in Japan (20-Aug-2013).
Patients who completed the core study and who in the in-
vestigator's clinical judgment beneﬁted from continued treatment
with omalizumab were eligible for the extension study. Patientsscreening period, a 24-week treatment period, and a follow-up investigation for anti-
t period and an optional follow-up investigation for anti-omalizumab antibody at 16
umab) was at the same day of follow-up investigation for anti-omalizumab antibody of
for the pediatric indication in Japan (20-Aug-2013). y16 weeks after the last dosing.
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hepatic failure, renal failure).
Omalizumab 75e375 mg was administered every 2 or 4 weeks
by subcutaneous injection, with a dose and dose frequency the
same as in the core study unless there were signiﬁcant changes in
body weight. If a dose adjustment was required, it was deter-
mined by the serum total IgE level (IU/mL) at the start of the core
study and the updated (current) body weight (kg) according to the
standard dosing table.16
Use of any asthma medications in line with the Japanese pedi-
atric guideline for the treatment and management of asthma 2008
(JPGL2008)17 were allowed throughout the extension study. No
prohibited medications were applied.
The extension study was conducted in accordance with good
clinical practice and the Declaration of Helsinki, and the protocol
was approved by each institution's ethics committee. Parents or
legal guardians were informed of study procedures and medica-
tions, and provided written informed consent before their child's
enrollment. The extension study was registered at http://
clinicaltrials.gov with the identiﬁer: NCT01328886.Table 1
Demographic and clinical characteristics at the start of the studies.
Core study Extension study
N ¼ 38 N ¼ 38
Age (years), mean (SD) 10.7 (2.46) 11.5 (2.52)
Age distribution (years), n (%)
6e9 14 (36.8) 11 (28.9)
10 24 (63.2) 27 (71.1)
Sex, n (%)
Male 23 (60.5) 23 (60.5)
Female 15 (39.5) 15 (39.5)
Duration of asthma (years),
mean (SD)
8.4 (3.05) 9.3 (3.08)
Total serum IgE (IU/mL),
median (range)
335.5 (33.6e1050.0) e
FEV1.0 (% of predicted), mean
(SD)
90.3 (19.34) 89.8 (18.63)y
FEF25e75% (% of predicted),
mean (SD)
76.3 (27.23) 75.0 (28.11)y
Number of hospitalizations due
to asthma in the previous
year, mean (SD)
1.4 (1.69) e
1 hospitalizations due to
asthma in the previous year,
n (%)
22 (57.9) e
Number of ER visitsy due to
asthma in the previous year,
mean (SD)
0.7 (1.09) e
1 ER visitsz due to asthma in
the previous year, n (%)
14 (36.8) e
Asthma control evaluated by JPAC score
Completely controlled e 3 (7.9)
Well controlled e 6 (15.8)
Not controlled e 29 (76.3)
ICS dose (mg/day, ﬂuticasone propionate equivalent)
Mean (SD) 469.7 (199.84) 459.2 (207.58)
Median (range) 500 (250e1000) 450 (200e1000)
Asthma long-term control medications, n (%)
Leukotriene receptor
antagonists
37 (97.4) 36 (94.7)
Long-acting b2-agonists 37 (97.4) 35 (92.1)
Sustained-release
theophylline preparations
23 (60.5) 18 (47.4)
Sodium cromoglycate 3 (7.9) 2 (5.3)
Oral corticosteroids 0 0
Dosing regimen of omalizumab, n (%)
Every 2 week 15 (39.5) 15 (39.5)
Every 4 week 23 (60.5) 23 (60.5)
ER, emergency room; FEV1, forced expiratory volume in one second; ICS, inhaled
corticosteroid; JPAC, Japanese pediatric asthma program; SD, standard deviation.
y n ¼ 37.
z If hospitalization and ER visit occurred on the same day, the event is counted as
hospitalization.Study assessments
The objectives of the extension study were to evaluate
long-term safety, efﬁcacy, pharmacokinetics and pharmacody-
namics of omalizumab in children with severe uncontrolled
asthma.
The primary outcome was the long-term safety and tolera-
bility of omalizumab. Safety assessments consisted of recording
adverse events (AEs) and serious adverse events (SAEs) during
the treatment period, vital signs, and any clinically signiﬁcant
changes in laboratory values that were evaluated at 1 month, 3
months and 6 months after the start of the extension study and
every 6 months thereafter. Anti-omalizumab antibodies (IgG)
were optionally measured at 16 weeks after the ﬁnal dose using
an enzyme-linked immunosorbent assay (ELISA) as previously
described.18
The other outcomes included asthma control, quality of life
(QOL), use of asthma controller medications, and spirometry
measurements that were evaluated every 3 months, the number of
hospitalizations and emergency room (ER) visits due to asthma,
and serum trough concentrations of omalizumab, free and total IgE
measured every 6 months.
Asthma control was assessed according to Japanese pediatric
asthma control program (JPAC) questionnaire,19 which consisted of
5 questions scored between 0 and 3 each (0 ¼ severe impairment;
3 ¼ no impairment), using the following scale: Completely
controlled (maximum score; 15 points), Well-controlled (12e14
points), Not controlled (11 points or less). QOL was measured using
the “QOL questionnaire for pediatric patients with bronchial
asthma and their parents or caregivers-short form version 2008
(Gifu)”,20 which consists of a physical (sum of the components of
asthma attack, instability of symptoms, exercise load) and an
emotional (sum of the components of emotional burden and proper
acceptance of asthma) domain, with each component consisting of
2 items each scored between 1 and 5 (1 ¼ severe impairment;
5 ¼ no impairment). Total IgE concentrations were quantiﬁed by
the ImmunoCAP100 (Phadia, Uppsala, Sweden) and free IgE and
omalizumab concentrations were determined using previously
reported ELISAs.21,22
The evaluation of asthma control based on JPAC questionnaire
was conducted during the extension study only and the other as-
sessments were performed throughout the core and extension
studies.Statistical analysis
The all safety and efﬁcacy analyses were performed on the
population, which consisted of all patients who received at least
one dose of omalizumab during the extension study. The phar-
macokinetics and pharmacodynamics variables were analyzed in
the populationwhich consisted of all patients who received at least
one dose of omalizumab and had at least one serum concentration
data during the extension study.
Descriptive statistics were used to summarize safety and efﬁ-
cacy variables. Asthma control evaluated by JPAC scores and mean
JPAC scores were summarized by visit. The 95% CIs for the mean
change from baseline in JPAC scores were calculated and p-values
were provided using the one sample t-test at each post-baseline
visit. The frequencies of hospitalizations or ER visits for asthma
and QOL scores during the extension study were compared with
the baseline of the core study within patient using the Wilcoxon
signed-rank test in patients with a value at both baseline and a
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of serum total IgE levels were made using Wilcoxon signed-rank
test. For other efﬁcacy variables, the changes during the exten-
sion study were summarized to compare with baseline of the core
study. In by-visit summaries, missing values were imputed using
the last observation carried forward (LOCF) approach, as appro-
priate. Values at the last visit of the extension study were sum-
marized as the assessment of “the end of the treatment period
(EOT)” regardless of the patient's study duration. Percent predicted
values of each spirometry measurements were calculated accord-
ing to the formula developed by the Japanese society of pediatric
pulmonology.23
Results
Baseline demographics and clinical characteristics
A total of 38 patients completed the core study and entered the
extension study. Of these, 35 patients (92.1%) completed the
extension study. Three patients (7.9%) discontinued the extension
study prematurely due to withdrawal of consent (2 patients) and
unsatisfactory therapeutic effect (1 patient). The median exposure
to omalizumab in the extension study was almost 2 years [92.4
weeks (range, 22.1e128.0 weeks)] and 13 patients (34.2%)Table 2A
Incidence of adverse events (preferred term) during the treatment period of the
extension study.
N ¼ 38
n (%)
Patients with any adverse event 38 (100.0)
Discontinued due to adverse event 0
Patient with serious adverse events 10 (26.3)
Asthma (asthma exacerbation) 7 (18.4)
Other than asthma (asthma exacerbation) 4 (10.5)
Most frequent adverse eventsy
Nasopharyngitis 20 (52.6)
Inﬂuenza 15 (39.5)
Upper respiratory tract infection 14 (36.8)
Asthma 13 (34.2)
Headache 11 (28.9)
Eczema 10 (26.3)
Pyrexia 9 (23.7)
Contusion 8 (21.1)
Enterocolitis 7 (18.4)
Pharyngitis 7 (18.4)
Stomatitis 7 (18.4)
Gastroenteritis 6 (15.8)
Ligament sprain 6 (15.8)
Vomiting 6 (15.8)
Conjunctivitis allergic 5 (13.2)
Upper respiratory tract inﬂammation 5 (13.2)
Urticaria 5 (13.2)
Acne 4 (10.5)
Injection site swelling 4 (10.5)
Otitis externa 4 (10.5)
Rhinitis allergic 4 (10.5)
Abdominal pain 3 (7.9)
Bronchitis 3 (7.9)
Constipation 3 (7.9)
Dermatitis allergic 3 (7.9)
Diarrhea 3 (7.9)
Growing pains 3 (7.9)
Hand fracture 3 (7.9)
Migraine 3 (7.9)
Myalgia 3 (7.9)
Pneumonia 3 (7.9)
Patients with any drug-related adverse events 11 (28.9)
Most frequent drug-related adverse eventsy
Injection site swelling 4 (10.5)
y In three or more patients.experienced 104 weeks (2 years) of treatment, though the dura-
tion of exposure to omalizumab varied from patient to patient due
to the different time (date) of the entry to the core study. The
median exposure throughout the core and extension studies
(excluding the follow-up period of the core study) was 116.6 weeks
(range, 46.9e151.1 weeks) and 34 patients (89.5%) experienced
104 weeks of treatment. During the extension study, dose
adjustment (increase) of omalizumab from that of the core study
occurred in 17 patients (44.7%) due to signiﬁcant increases in body
weight.
Baseline demographics and clinical characteristics of the core
and extension studies are shown in Table 1. No major differences
were found between the studies. At the start of the extension study,
all patients used ICS, with a mean dose (FP equivalent) of 459.2 mg/
dayemore than double the maximum approved dose (200 mg/day)
for children in Japan e and most patients were using LTRA (94.7%)
and LABA (92.1%), respectively. 29 Patients (76.3%) had inade-
quately controlled asthma as evaluated by the JPAC score.Safety
All 38 patients experienced at least one AE during the treatment
period. The most common AEs (30%, preferred term) were naso-
pharyngitis, inﬂuenza, upper respiratory tract infection, and
asthma (Table 2A). Incidence of adverse events (system organ class)
in every 24 weeks didn't increase with increased exposure to
omalizumab (Table 2B).
Ten patients experienced at least one SAE during the treatment
period; asthma (asthma exacerbation) in 7 patients (3 exacerba-
tions in one patient; 2 exacerbations in one patient; an exacerba-
tion in each 5 patients) and SAEs other than asthma in 4 patients
(Tonsillitis bacterial and viral pharyngitis in one patient; peri-
tonsillar abscess and lymphadenitis in one patient; appendicitisTable 2B
Incidence of adverse events (system organ class) in every 24 weeks during the
treatment period of the core and the extension study (In three or more patients in
any evaluation period).
Study Core
N ¼ 38
Extension
N ¼ 38
Period (weeks) 0e24 0e24 >24e48 >48e72 >72e96
N ¼ 38 N ¼ 38 N ¼ 36 N ¼ 35 N ¼ 35
System Organ Class n (%) n (%) n (%) n (%) n (%)
Total adverse events 36 (94.7) 37 (97.4) 32 (88.9) 30 (85.7) 23 (65.7)
Infections and
infestations
31 (81.6) 27 (71.1) 23 (63.9) 19 (54.3) 17 (48.6)
Gastrointestinal
disorders
11 (28.9) 11 (28.9) 10 (27.8) 7 (20.0) 7 (20.0)
Respiratory, thoracic
and mediastinal
disorders
14 (36.8) 9 (23.7) 9 (25.0) 12 (34.3) 2 (5.7)
Skin and
subcutaneous tissue
disorders
8 (21.1) 6 (15.8) 10 (27.8) 4 (11.4) 5 (14.3)
Injury, poisoning and
procedural
complications
6 (15.8) 5 (13.2) 7 (19.4) 10 (28.6) 3 (8.6)
General disorders
and administration
site conditions
11 (28.9) 10 (26.3) 5 (13.9) 3 (8.6) 1 (2.9)
Nervous system
disorders
5 (13.2) 8 (21.1) 6 (16.7) 4 (11.4) 1 (2.9)
Musculoskeletal and
connective tissue
disorders
9 (23.7) 4 (10.5) 3 (8.3) 2 (5.7) 4 (11.4)
Eye disorders 2 (5.3) 4 (10.5) 4 (11.1) 4 (11.4) 1 (2.9)
Psychiatric disorders 0 3 (7.9) 1 (2.8) 0 0
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SAEs were due to hospitalization. One patient discontinued the
extension study during the SAE of asthma (asthma exacerbation)
due to unsatisfactory therapeutic effect, because the investigator
considered omalizumab was not effective for the improvement of
asthma symptoms. Only the SAE of peritonsillar abscess was sus-
pected to be drug-related by the investigator. The investigator re-
ported that the event was highly considered due to upper
respiratory tract infection because upper respiratory inﬂammation
caused by virus infection had developed 17 days before it and
continued. However, as the event developed 5 days after the latest
administration of omalizumab, its relation with omalizumab was
not completely denied and judged as drug-related (The category of
causal relationship with the drug in the extension study was
“related” or “not-related”). The event resolved completely in 8 days
with additional treatments of hydrocortisone sodium succinate
(Saxizon® for injection), sulbactam sodium and ampicillin sodium
(Sulbacillin® for injection), and glucose-electrolyte solution (Sol-
dem® 3A).
No AEs of particular clinical interest of anaphylactic reactions,
malignancies, serum sickness, Churg-Strauss syndrome, thrombo-
cytopenia, or arterial thromboembolic events were reported during
the treatment period. Follow-up investigation for anti-omalizumab
antibodies was performed in 10 patients and no anti-omalizumab
antibodies were detected.Asthma control evaluated by JPAC score during the extension study
Treatment with omalizumab led to marked improvements in
asthma control as assessed by JPAC score (Fig. 2). At the end of the
treatment period, 29 patients (76.3%) achieved complete or well-
controlled asthma compared with 9 patients (23.7%) at the start
of the extension study. The JPAC score itself also showed a statis-
tically signiﬁcant improvement. The mean JPAC score (SD) was 9.9
(2.80) at the start of the extension study, and themean change from
baseline (95% CI) was [2.6 (1.5, 3.6), p < 0.001 one sample t-test ] at
week 48, [2.9 (1.9, 3.8), p < 0.001 one sample t-test] at week 96, and
[3.0 (2.0, 4.0), p < 0.001 one sample t-test] at the end of the
treatment period, respectively.Fig. 2. Patients' asthma control (completely controlled, well controlled, not controlled)
and JPAC score over the treatment period of the extension study. Data points are mean
and vertical bars are standard deviation in JPAC score. yEOT: Values at the last visit of
the extension study were summarized as the assessment of “the end of the treatment
period (EOT)” regardless of the patient's study duration.
Fig. 3. Rate (per patient-year) of hospitalizations (A) and ER visits (B) due to asthma
over each evaluation periods [core study: baseline (previous 12 months before the start
of the core study plus the screening period), 24 weeks of the treatment period, follow-
up period, extension study: 0e48 weeks and >48e96 weeks of the treatment period,
total treatment period]. Each rate was derived from the total number of events
observed during the corresponding evaluation period divided by the total amount
time/exposure (in years) of the patients in that period. If hospitalization and ER visit
occurred on the same day, the event was counted as a hospitalization. Overall QOL
score over the core study and the extension study (C). The boxes indicate the median,
the 25th and 75th percentiles, whereas the extremes represent the minimum and
maximum values. The analysis was performed in patients who had a baseline and at
least one post-baseline assessment of QOL (n ¼ 37). QOL was measured using the “QOL
questionnaire for pediatric patients with bronchial asthma and their parents or
caregivers-short form version 2008 (Gifu)”. yEOT: Values at the last visit of the
extension study were summarized as the assessment of “the end of the treatment
period (EOT)” regardless of the patient's study duration.
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The rate of hospitalizations due to asthma per patient-year was
0.16 over the all treatment period during the extension study,
comparedwith1.33 atbaselineof the core study (previous12months
before the start of the core study plus the screening period), repre-
senting a reduction of 88.0% versus baseline (p < 0.001 Wilcoxon
signed-rank test, Fig. 3A). In addition, the rate of hospitalizations
during the two evaluation periods (0e48 weeks, >48e96 weeks) of
the extension study and that of the 24-week treatment period of the
core study were comparable. The rate of ER visits per patient-year
during the all treatment period of the extension study was signiﬁ-
cantly lower compared with the baseline (0.68 vs 0.15, p ¼ 0.002
Wilcoxon signed-rank test, Fig. 3B). In addition, the rates of ER visits
during the two evaluation periods (0e48 weeks, >48e96 weeks) of
the extension study tended to be lower than that of the 24-week
treatment period of the core study, which is insigniﬁcant.
Quality of life
Overall QOL scores at week 48, week 96 and the end of the
treatment period of the extension study reached almost the upper
limit of the ranges (Fig. 3C), and showed statistically signiﬁcant
improvements compared with the baseline of the core study
[Median, 39.0 (n¼ 35) vs 46.0 (n¼ 35) for week 48, 42.0 (n¼ 27) vs
48.0 (n ¼ 27) for week 96, 39.0 (n ¼ 37) vs 48.0 (n ¼ 37) for end of
the treatment period, p < 0.001 respectively, Wilcoxon signed-rank
test]. Similar results were obtained in physical domain and
emotional domain scores, respectively [e.g. median, 24.0 (baseline,Table 3A
Summary of usage of asthma long-term controller medications.
Asthma long-term medications Core study
N ¼ 38, n (%)
Baseline End
N ¼ 38 N ¼
Inhaled corticosteroid 38 (100) 38 (
Leukotriene receptor antagonists 37 (97.4) 35 (
Long-acting b2-agonists 37 (97.4) 34 (
Sustained-release theophyllines 23 (60.5) 19 (
Sodium cromoglycate 3 (7.9) 2 (
Patients with stopping any medications compared to baseline e 8 (
3 medications stopped e 1 (
2 e 0
1 e 7 (
Patients with adding any medications compared to baseline e 0
Table 3B
Summary of usage of Inhaled corticosteroid (ICS).
Core study
N ¼ 38, n (%)
Baseline End of trea
N ¼ 38 N ¼ 38
No of patients with ICS 38 (100) 38 (100)
Mean (SD), (mg/day) 469.7 (199.84) 455.3 (211
Median (range), (mg/day) 500 (250e1000) 450 (200e
No of patients with reduction of ICS doses compared to
the baseline
e 4 (10.5)
>400 (mg/day) of reduction e 0
>200e400 (mg/day) e 1 (2.6)
>100e200 (mg/day) e 1 (2.6)
>50e100 (mg/day) e 0
>0e50 (mg/day) e 2 (5.3)
No of patients with increase of ICS doses compared to
the baseline
e 0
ICS, inhaled corticosteroid.n¼ 37) vs 29.0 (end of the treatment period, n¼ 37) for the physical
domain, and 15.0 (baseline, n ¼ 37) vs 19.0 (end of the treatment
period, n ¼ 37) for the emotional domain (p < 0.001 respectively,
Wilcoxon signed-rank test)].Use of asthma controller medications
Use of long-term control medications for asthma is summarized
in Table 3A. At the end of the treatment period of the extension
study, the number of patients who used theophylline was almost
half compared with the baseline of the core study [23 patients
(60.5%) vs 12 patients (31.6%)]. Fifteen patients (39.5%) stopped at
least one asthma long-term control medication compared with the
baseline of the core study, while 8 patients (21.1%) at the end of the
treatment period of the core study. Although all patients used ICS
throughout the core and extension studies, 14 patients (36.8%) had
dose reductions of ICS compared with baseline of the core study,
while only one patient (2.6%) had a dose increase (increase of
100 mg/day) (Table 3B). The change from baseline of the core study
in mean ICS doses (% change) was 64.5 mg/day (13.2%).Spirometry measurements (FEV1 and FEF25e75%)
Little changes were observed in mean FEV1 (% predicted) and
FEF25e75% (% predicted) values throughout the core and extension
studies [e.g. mean (SD), 90.3 (19.34)% at the baseline of the core
study vs 89.2 (15.83)% at the end of the treatment period of the
extension study for FEV1 (% predicted), and 76.3 (27.23)% at theExtension study
N ¼ 38, n (%)
of treatment Week 0 Week 48 Week 96 End of treatment
38 N ¼ 38 N ¼ 36 N ¼ 27 N ¼ 38
100) 38 (100) 36 (100) 27 (100) 38 (100)
92.1) 36 (94.7) 33 (91.7) 25 (92.6) 35 (92.1)
89.5) 35 (92.1) 31 (86.1) 24 (88.9) 33 (86.8)
50.0) 18 (47.4) 12 (33.3) 9 (33.3) 12 (31.6)
5.3) 2 (5.3) 0 0 0
21.1) 8 (21.1) 15 (41.7) 12 (44.4) 15 (39.5)
2.6) 1 (2.6) 1 (2.8) 0 1 (2.6)
0 2 (5.6) 2 (7.4) 3 (7.9)
18.4) 7 (18.4) 12 (33.3) 10 (37.0) 11 (28.9)
1 (2.6) 0 0 0
Extension study
N ¼ 38, n (%)
tment Week 0 Week 48 Week 96 End of treatment
N ¼ 38 N ¼ 36 N ¼ 27 N ¼ 38
38 (100) 36 (100) 27 (100) 38 (100)
.11) 459.2 (207.58) 430.6 (202.58) 392.6 (243.65) 405.3 (210.79)
1000) 450 (200e1000) 400 (200e1000) 350 (200e1000) 400 (200e1000)
5 (13.2) 9 (25.0) 12 (44.4) 14 (36.8)
1 (2.6) 1 (2.8) 1 (3.7) 1 (2.6)
1 (2.6) 1 (2.8) 3 (11.1) 3 (7.9)
1 (2.6) 3 (8.3) 2 (7.4) 2 (5.3)
0 0 1 (3.7) 2 (5.3)
2 (5.3) 4 (11.1) 5 (18.5) 6 (15.8)
2 (5.3) 1 (2.8) 0 1 (2.6)
Fig. 4. Mean (SD) plots over the core study and the extension study in (A) Free IgE concentrations (ng/mL), (B) Total IgE concentrations (ng/mL) and (E) omalizumab concentrations
(mg/mL) in dosing subgroups (every 2 weeks or 4 weeks dosing). For free IgE, if an observed value exceeded an upper limit of quantiﬁcation, 150 (ng/mL), the value was summarized
as 150 (ng/mL). Comparison of serum total IgE levels between the end of the treatment period of the core study (week 24) and that of the extension study in dosing subgroups of
every 2 weeks (C) and every 4 weeks (D). Each symbol shows an individual value; horizontal bars are median values. The analyses were performed in patients who received at least
one dose of omalizumab and had at least one serum concentration data during the extension study (n ¼ 37). yEOT: Values at the last visit of the extension study were summarized as
the assessment of “the end of the treatment period (EOT)” regardless of the patient's study duration.
H. Odajima et al. / Allergology International 66 (2017) 106e115112
H. Odajima et al. / Allergology International 66 (2017) 106e115 113baseline of the core study vs 75.1 (23.71)% at the end of the treat-
ment period of the extension study for FEF25e75% (% predicted)].
Serum free IgE, total IgE and omalizumab levels
In both dosing subgroups (every 2 weeks or 4 weeks), mean
serum free IgE levels prior to the ﬁrst dose of the extension study
(at the end of the washout of omalizumab during the follow-up
period of the core study) increased to 125e150 ng/mL (Fig. 4A).
After restarting treatment with omalizumab, the mean serum free
IgE levels were again suppressed below 25 ng/mL throughout the
treatment period of the extension study.
Mean serum total IgE levels during the extension study were
lower than those in the core study and exhibited a decrease with
time in both dosing subgroupswhichwasmore noticeable for those
taking omalizumab every 2weeks (Fig. 4B). Serum total IgE levels at
the end of the treatment period of the extension study showed a
43.9% reduction in 2-weekly dosing subgroup and 37.7% reduction
in 4-weekly dosing subgroup respectively, compared with that at
the end (week 24) of the treatment period of the core study [Me-
dian, 3790 ng/mL vs 2125 ng/mL, p < 0.001, for 2-weekly dosing
subgroup (Fig. 4C), 1580 ng/mL vs 984 ng/mL, p < 0.001, for 4-
weekly dosing subgroup (Fig. 4D)].
Mean trough omalizumab levels during the extension study
were comparable to those in the core study (Fig. 4E).
Discussion
This is, to the author's knowledge, the ﬁrst study to investigate,
comprehensively, the clinical safety, efﬁcacy and pharmacological
effects of long-term treatment with omalizumab in children with
uncontrolled severe asthma. Almost 90% of the patients received
104 weeks of treatment with omalizumab throughout the core
and extension studies, though the duration of exposure to omali-
zumab varied from patient to patient.
At the start of the extension study approximately 80% of the
patients had inadequately controlled asthma evaluated by JPAC
score, although all patients used200 mg/day of ICS (corresponding
to high dose ICS in JPGL2008) and 90% or more patients used LTRA
and LABA, respectively. In addition, some of the efﬁcacy parameters
including QOL score and rate of hospitalization seemed to worsen
compared with those at the end of the 24-week treatment period
(week 24) of the core study. This might be due to the 16-week-
follow-up after the last dosing of omalizumab in the core study, in
which omalizumab was not administered, enabling free IgE levels
to return toward baseline. This is consistent with the previous
report showing that withdrawal of omalizumab after less than a
year of treatment resulted in a return to the pre-treatment clinical
state within a few months.24
The safety proﬁle of omalizumab in the extension study was
comparable to that observed in previous studies,13e16 and no new
safety concerns were identiﬁed. In addition, there was no trend
toward an increase in incidence of adverse events with prolonged
exposure to omalizumab. Of all SAEs, peritonsillar abscess was
suspected to be drug-related, but completely resolved with addi-
tional treatments. To the author's knowledge, there is no evidence
that omalizumab induces increased susceptibility to viral or bac-
terial infection, where it might be associated with a modest in-
crease in helminth infection rate in patients at chronic high risk of
it.25 In randomized placebo-controlled studies in children with
asthma,13e15,26 incidences of adverse events associatedwith viral or
bacterial infections (e.g. nasopharyngitis, upper respiratory tract
infection and inﬂuenza) in omalizumab groups were comparable
with those in placebo groups. In addition, allergic asthma children
have impaired antiviral response via IgE-dependentmechanism,27,28 increasing the chance of frequent and severe
virus-induced exacerbations,29 and thus it may be possible that
omalizumab affects that process.
Long-term treatment with omalizumab in the extension study
led to marked and sustained improvements in asthma control
evaluated by JPAC score, QOL, frequencies of hospitalizations and
ER visits due to asthma, and use of asthma controller medications.
In addition, the rates of hospitalizations and ER visits due to
asthma during the two evaluation periods (0e48 weeks, >48e96
weeks) of the extension study were comparable with or lower than
those in the 24-week treatment period of the core study. These
results indicate that there is no loss of efﬁcacy with increased
exposure to omalizumab. Whether longer treatment with omali-
zumab provides more beneﬁcial clinical effects or not should be
further investigated.
Some previous studies investigated the ICS sparing effects of
omalizumab13e15,26,30 and the extent of ICS dose reduction differed
according to the study designs and severity of the patients. How-
ever, as children with severe asthma are usually treated with high
dose ICS and other controller medications, dose reduction of not
only ICS but also other controller medications should be evaluated.
At the end of the treatment period of the extension study,
approximately 40% of the patients stopped at least one asthma
long-term control medication and reduced ICS doses compared
with baseline of the core study, respectively. Order and amount of
reduction in asthma controller medications in the extension study
was based on investigator's decision, and therefore, presenting the
most appropriate scheme of reduction of asthma controller medi-
cations would be an important upcoming question.
The mean serum free IgE level was suppressed below 25 ng/mL
(target level of suppression) throughout the treatment period of
the extension study, supporting the long-term efﬁcacy of omali-
zumab as described above.
Though there is the limitation of interpretation due to the small
sample size and the study design (single-arm, open-label), these
consistent improvements in asthma control with long-term treat-
ment with omalizumab, which were ﬁrst demonstrated in this
extension study, would strongly support the role of omalizumab in
the management of children with severe allergic asthma.
Overall, omalizumab was associated with little change in lung
function throughout the core and extension studies though other
clinical variables were markedly improved. It raises several
possible hypotheses. One is that as study patients had early-onset
(the mean age and duration of asthma at the baseline of the core
study were 10.7 years and 8.4 years, respectively) severe persis-
tent asthma, having frequent exacerbations despite receiving the
current recommended therapies, they are thought to have less
reversible changes in airway wall stricture.31,32 Omalizumab,
which is not a direct bronchodilator, might not be effective
enough to show improvement in lung function in stable condition
in such population though it has been shown to reduce allergen-
induced bronchoconstriction in patients with mild or moderate
asthma.33,34 Another is that though spirometry is currently the
most commonly used test to measure lung functions, impulse
oscillometry, which is an alternative, noninvasive, and effort-
independent approach35,36 and could have greater sensitivity to
detect peripheral airway obstruction,37,38 has newly been devel-
oped. Therefore, it may be worth to be performed to ﬁnd an effect
undetectable by spirometry. The other is that considering a pro-
gressive decline in lung function over time observed in children
and adolescents with severe asthma,2,39 omalizumab could have
beneﬁt to prevent it, which requires much more time in follow-up
to be proved.
Several randomized studies have established omalizumab is
effective and well-tolerated as add-on therapy in pediatric patients
H. Odajima et al. / Allergology International 66 (2017) 106e115114with moderate to severe allergic asthma,13e15 but the impact of
long-term treatment with omalizumab on the natural course of
asthma has not beenwell-investigated. There is some evidence that
omalizumab might have a disease-modifying effect. Nopp et al.
reported that most of the patients who had stopped omalizumab
after approximately 6 years of treatment had stable or improved
asthma control for 3 years after stopping.40 Lowe et al. have sug-
gested by using the model-based pharmacokineticepharmacody-
namic analysis that IgE production in patients with allergic asthma
might be reduced during long-term treatment with omalizumab.41
It is generally known that after initiation of omalizumab treatment,
serum total IgE level is increased due to differences in metabolic
pathways between free IgE and IgE-omalizumab complexes (longer
metabolic half-life of IgE-omalizumab complexes than that of free
IgE), kept at a constant increased level during the treatment of
omalizumab, and decreased to the baseline level after cessation of
omalizumab.24,42 In the core study, serum total IgE level changed as
previously reported. However, in this extension study, after
restarting of treatment with omalizumab, serum total IgE levels
was at ﬁrst increased, but then demonstrated a decreasing trend,
while exposure to omalizumab remained at a steady state. As a
result, serum total IgE levels at the end of the treatment period of
the extension study showed approximately 40% reduction
compared to that at the end of the treatment period (week 24) in
the core study. Considering that trough omalizumab levels were
kept constant during the core and extension studies and that serum
IgE levels in patients with asthma in childhood generally show an
increasing trend,43,44 this new observation of change in serum total
IgE levels in the extension study may also indicate that longer
exposure to omalizumab could reduce IgE production. There is a
possibility that the decreasing trend of serum total IgE correlates
with sustainable asthma control after cessation of omalizumab
treatment; or growing out of asthma. However, after the extension
study most patients continued treatment with omalizumab
(Xolair®), and therefore, asthma control, total and free IgE levels
after stopping long-term treatment with omalizumab could not be
investigated. Further detailed study on IgE production and disease
prognosis of asthma over long-term treatment with omalizumab
should be required.
In conclusion, this study indicates that long-term treatment
with omalizumab as add-on therapy to current standard of care is
well-tolerated and effective in children with uncontrolled severe
allergic asthma. Increase in safety risks or loss of efﬁcacy with
extended exposure to omalizumab was not identiﬁed.Acknowledgments
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